About
Small Molecules Acting on Stem Cells
Areas of Focus
Categories
Small Molecule PharmaceuticalSan Diego & Southern California
Team (8)
Allan Gibofsky
Clinical Advisor
Biosplice Therapeutics
advisor
Dr. Lamees Hamdan
Special Advisor
Biosplice Therapeutics
advisor
Jeffrey L. Cummings, MD, ScD
Scientific Advisor
Biosplice Therapeutics
advisor
John A. Bergfeld, MD
Clinical Advisor
Biosplice Therapeutics
advisor
Morgan Jones, MD, MPH
Clinical Advisor
Biosplice Therapeutics
advisor
Nancy E. Lane, MD
Clinical Advisor
Biosplice Therapeutics
advisor
Clinical Trials (24)
View allTotal Trials
24
As Lead Sponsor
22
As Collaborator
2
Total Enrollment
5,409
By Phase
PHASE1/PHASE2: 1PHASE2: 8PHASE3: 5PHASE1: 8PHASE2/PHASE3: 1
By Status
COMPLETED: 16TERMINATED: 5NOT_YET_RECRUITING: 1RECRUITING: 1WITHDRAWN: 1
Clinical Trials Pipeline24 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT07155200Collaborator
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
PHASE1/PHASE2Not yet recruiting
42 participants
Started: Dec 31, 2025 · Completed: Jan 31, 2029
NCT07032285Collaborator
Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas
PHASE2Recruiting
25 participants
Started: Jan 15, 2025 · Completed: Jul 30, 2027
NCT05603754Lead Sponsor
A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES)
PHASE3Completed
496 participants
Started: Nov 18, 2022 · Completed: Feb 20, 2024
NCT05084859Lead Sponsor
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
PHASE1Terminated
30 participants
Started: Nov 3, 2021 · Completed: Oct 20, 2022
NCT04931667Lead Sponsor
3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Subjects With Osteoarthritis of the Knee
PHASE3Terminated
73 participants
Started: Jul 15, 2021 · Completed: Dec 13, 2021
Locations (1)
Headquarters
San Diego, CA, United States
Map
Loading map...